VTYX Stock Recent News
VTYX LATEST HEADLINES
NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- If you are a shareholder of Ventyx Biosciences (NASDAQ: VTYX), you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation or contacting us below. Why is Ventyx Being Investigated by BFA?
NEW YORK, NY / ACCESSWIRE / June 12, 2024 / If you are a shareholder of Ventyx Biosciences (Nasdaq: VTYX), you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation or contacting us below. Why is Ventyx Being Investigated by BFA?
NEW YORK, NY / ACCESSWIRE / June 11, 2024 / If you are a shareholder of Ventyx Biosciences (Nasdaq:VTYX), you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation or contacting us below. Why is Ventyx Being Investigated by BFA?
NEW YORK, June 11, 2024 (GLOBE NEWSWIRE) -- If you are a shareholder of Ventyx Biosciences (NASDAQ: VTYX), you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation or contacting us below. Why is Ventyx Being Investigated by BFA?
NEW YORK, June 08, 2024 (GLOBE NEWSWIRE) -- If you are a shareholder of Ventyx Biosciences (NASDAQ: VTYX), you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation or contacting us below.
NEW YORK, NY / ACCESSWIRE / June 7, 2024 / If you are a shareholder of Ventyx Biosciences (NASDAQ:VTYX), you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation or contacting us below. Why is Ventyx Being Investigated by BFA?
NEW YORK, June 06, 2024 (GLOBE NEWSWIRE) -- If you are a shareholder of Ventyx Biosciences (NASDAQ: VTYX), you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation or contacting us below.
VTX3232 demonstrated improvements in body weight, systemic inflammatory biomarkers and cardiometabolic parameters in diet-induced obesity (DIO) mice
NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Ventyx Biosciences, Inc. (NASDAQ: VTYX) on behalf of long-term stockholders following a class action complaint that was filed against Ventyx on March 1, 2024 with a Class Period pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's initial public offering conducted on or about October 21, 2021 (the “IPO” or “Offering”); and/or (b) from October 21, 2021 to November 6, 2023. Our investigation concerns whether the board of directors of Ventyx have breached their fiduciary duties to the company.
SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in the following upcoming investor conferences: